Cibrik Diane M, Kaplan Bruce, Campbell Darrell A, Meier-Kriesche Herwig-Ulf
Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
Am J Transplant. 2003 Jan;3(1):64-7. doi: 10.1034/j.1600-6143.2003.30111.x.
Previous literature suggests that the recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is more common in recipients who have received an HLA-identical living-related (LRD) transplant. To address the question if FSGS patients can safely receive a 6-antigen match LRD kidney transplant, we analyzed death-censored renal allograft survival data of FSGS patients from the United States Renal Data System database (USRDS). Using the USRDS and the U.S. Scientific Renal Transplant Registry between the years 1988-97, we found 19259 adult primary renal transplant recipients, of which 2414 patients had FSGS as their primary diagnosis as compared to 16845 patients who had other types of glomerulonephritis (GN). A Cox proportional hazard model was used to estimate death-censored graft survival among FSGS patients with a zero mismatch LRD kidney transplant. The model included a triple interaction term comparing FSGS vs. GN vs. living donation (LD) vs. cadaveric donation (CAD) vs. zero mismatch (six antigen or HLA-identical) vs. mismatch. Annually adjusted death censored graft loss rates per 1000 patients (ADGL) were calculated. Focal segmental glomerulosclerosis patients receiving a zero mismatch LRD kidney transplant had the lowest ADGL rate, losing 10.5 grafts per 1000 patients per year. Not significantly different but higher (14.3) was the ADGL rate for LD, zero mismatch GN recipients. The ADGL rate was significantly higher in FSGS recipients who received a LD, mismatched transplant (36.5). Focal segmental glomerulosclerosis patients who received a CAD, zero mismatched graft (44.1), or CAD, mismatched graft (63.2), had significantly higher ADGL rates. Zero mismatch LRD kidney transplants are not a risk factor for graft loss in FSGS patients but are associated with significantly better death-censored graft survival as compared to CAD 6-antigen match or mismatched donations.
既往文献表明,肾移植后局灶节段性肾小球硬化(FSGS)复发在接受了 HLA 全相合亲属活体(LRD)移植的受者中更为常见。为了探讨 FSGS 患者是否能够安全地接受 6 抗原匹配的 LRD 肾移植,我们分析了来自美国肾脏数据系统数据库(USRDS)中 FSGS 患者的死亡校正肾移植存活率数据。利用 1988 年至 1997 年间的 USRDS 和美国科学肾脏移植登记处的数据,我们找到了 19259 例成人初次肾移植受者,其中 2414 例患者以 FSGS 作为主要诊断,相比之下,有 16845 例患者患有其他类型的肾小球肾炎(GN)。使用 Cox 比例风险模型来估计接受零错配 LRD 肾移植的 FSGS 患者的死亡校正移植存活率。该模型包括一个三重交互项,用于比较 FSGS 与 GN、活体捐赠(LD)与尸体捐赠(CAD)、零错配(六个抗原或 HLA 全相合)与错配情况。计算了每 1000 例患者每年校正的死亡校正移植丢失率(ADGL)。接受零错配 LRD 肾移植的局灶节段性肾小球硬化患者的 ADGL 率最低,每年每 1000 例患者中有 10.5 例移植丢失。LD 零错配 GN 受者的 ADGL 率虽无显著差异但更高(14.3)。接受 LD 错配移植的 FSGS 受者的 ADGL 率显著更高(36.5)。接受 CAD 零错配移植(44.1)或 CAD 错配移植(63.2)的局灶节段性肾小球硬化患者的 ADGL 率显著更高。零错配 LRD 肾移植不是 FSGS 患者移植丢失的危险因素,但与 CAD 6 抗原匹配或错配捐赠相比,其死亡校正移植存活率显著更好。